25 Apr 2017 | 12:54 PM
 

Natco Pharma Ltd. Share Price Live (BSE)
0

BSE Code: 524816 | NSE Symbol: NATCOPHARM
926.05
-0.90
(-0.09 %)
25 Apr 2017 | 12:46 PM
Change company
  • Open (Rs)
    929.00
  • Prev. close (Rs.)
    926.95
  • High (Rs.)
    940.00
  • Low (Rs.)
    917.00
  • 52W H (Rs.)
    1,015.00
  • 52W L (Rs.)
    440.00
  • Volume (Rs.)
    42718
  • MCap (Rs in Cr.)
    16,141.80
0
0.00
(0.00 %)
  • Open (Rs)
    0.00
  • High (Rs)
    0.00
  • Low (Rs)
    0.00
  • Prev. close(Rs)
    0.00
  • Contracts Tra.
  • Turnover (Cr.)
    N.A.
  • Open Interest
  • Open Int. chg
    0.00
1D| 1W| 1M | 3M | 6M | 1YR | MAX

Financials

EPS
8.91
Operating Margin (%)
23.62
Gross Profit Margin (%)
19.16
Net Profit Margin (%)
13.59
Total Debt/Equity
0.08
Dividend payout Ratio (Net Profit)
16.88
Earning Retention Ratio
83.49

News

31 Jan 2017 - 12:25:00-Drug maker Natco Pharma Ltd on Tuesday said that the US District Court has ruled in favour of Mylan ...
25 Jan 2017 - 11:54:00-Natco Pharma today said the US health regulator has made six observations after the completion of in...
06 Jan 2017 - 14:36:00-Natco Pharma Ltd today said it has received final approval from USFDA for Bendamustine injection...
02 Jan 2017 - 17:04:00-Drug maker Natco Pharma Ltd on Monday said it has launched the first generic version of Sofosbuvir 4...

Announcements

17-Apr-2017
Natco Pharma - 31St March 2017
17-Apr-2017
Natco Pharma - Certificate Under Clause 40 (10) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 20
07-Apr-2017
Natco Pharma - Shareholding for the Period Ended March 31 2017
16-Feb-2017
Natco Pharma - Investor Presentation
14-Feb-2017
Natco Pharma - Announces Q3 results (Standalone & Consolidated) Limited Review Report (Standalone & Consolidated) & Results

Religare Research

24 Apr 2017 | 07:39 PM
• Gold prices edged higher on Friday as investors remained cautious ahead of the first round of voti...
24 Apr 2017 | 06:00 PM
Tech Stars, comprises our 2 top stock picks filtered on the basis of momentum from our coverage univ...
24 Apr 2017 | 09:50 AM
Gold falls as stocks gain after French election result Oil dives, U.S. crude below $50 for first tim...
24 Apr 2017 | 09:45 AM
The Indian rupee ended lower for a second consecutive week, posting its biggest weekly fall since De...

Fund Interest

Schemes Shares Held Mkt. Value Latest Nav % Nav
4,00,000 90.05 31.45 0.80
4,00,000 90.05 132.91 0.79
4,00,000 90.05 138.60 0.80
4,00,000 90.05 50.44 0.80
1,60,000 35.89 99.35 -0.64

Shareholding Pattern

       
Promotors51.24%
Mutual Funds/UTI5.01%
FI/Banks2.28%
Insurance2.28%
FII19.41%
Government0.00%
Others3.38%

Peer Group

Company Intraday Graph
 Sanofi India Ltd.
4,300.00(-2.08)
3325
 Dr. Reddy`s Laboratories Ltd.
2,620.00(0.45)
3294
 GlaxoSmithKline Pharmaceuticals Ltd.
2,570.00(-0.26)
3317
 Piramal Enterprises Ltd.
2,500.00(2.04)
3356

Exchange Information

NSE Index
Sensex
CNX 100
BSENAT
CNX 200
BSE200
CNX Bank
BSE500
CNX500
BSE Midcap
CNX Midcap
BSE Smallcap
Note: The scrip is a constituent of those NSE and BSE indices that have against them.

Company Indices

 1M (%)3M (%)6M (%)
Natco Pharma Ltd.142.25287.45328.75
NIFTY(S&P CNX)176.75808.95575.80
BSE SENSEX459.032,504.851,701.35
BSE 500477.561,398.341,010.25

Corporate Details

Key Personal
A K S Bhujanga Rao
Director & President (R&D and Tech.)
A K S Bhujanga Rao
President & Director
D Linga Rao
Director & President (Tech. Affairs)
Key Address
Registered Office
Natco House Road No.2 Banjara Hills,Hyderabad,Telangana

Tel:040-23547532, Fax:040-23548243

investors@natcopharma.co.in
http://www.natcopharma.co.in
Registrar Office
Venture Capital & Corporate Investments Pvt. Ltd.
Add. :No. 12-10-167 Bharat Nagar

Make smart investment decisions with Star Ratings, a stock selection tool, based upon fundamental, technical and analyst recommendations. Star Ratings provides stock trading tips for Natco Pharma Ltd. that will help you decide whether to buy, sell or hold Natco Pharma Ltd. It also provides you with switch proposals on alternative stocks, i.e., which stocks to buy against Natco Pharma Ltd.